

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 31 January 2021

Situation Report No. 224 - Kingdom of Bahrain
1st of February, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	102,083,344	2,209,195	5,669,871	134,186
New	501,930	11,986	21,267	695

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	103,057	98,599	375	4,083	28	2,713,722
New	431	439	3	-	-	12,637

HIGHLIGHTS

- The mortalities were: 54 and 63 year old Bahraini male citizens and a 83 year old Bahraini female citizens.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 31 January 2021 is 171,568.
- HRH the Crown Prince and Prime Minister addressed the nation on COVID-19 update.
- Minister of Health praised Bahraini families, lauding contributions in support of the health sector.
- Minister of Health called for a greater adherence to precautionary measures in order to curb the spread of the Coronavirus.
- MOH Undersecretary revealed that Bahrain has emergency plans in place to deal with COVID-19 spiking situation.
- Bahrain documented over 100% rise in new coronavirus infections in the past 10 days.
- Authorities emphasized the enforcement of zero tolerance policy towards restaurants, sheesha cafes and food stalls for violating COVID-19 public health protocols.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assay; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Draft landscape of COVID-19 candidate vaccines; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.


IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6d4976_4
- WHO: COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25vd5dr>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: [https://www.who.int/publications/i/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assays: <https://bit.ly/2l0hwWQ>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2l0hwWQ>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/i/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/i/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/i/item/10665337553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: <https://www.who.int/publications/i/item/WHO-2019-nCoV-EU-2020-01>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-\(pfizer-biontech\)-against-covid-19](https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/21-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/i/item/9789240018440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Draft landscape of COVID-19 candidate vaccines: <https://www.who.int/publications/i/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: https://www.who.int/publications/i/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: [https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-\(pfizer-biontech\)-against-covid-19](https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19)
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-efficacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic: [https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/publications/i/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>


IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAI5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh

Number of New Cases



Total Number of Cases



Number of New Deaths

